By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Minimal Residual Disease (MRD)56.79M60.43%
Immune Medicine37.19M39.57%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States178.96M100.00%